Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma

Abstract

BACKGROUND: Intrahepatic arterial yttrium 90 (⁹⁰Y) microspheres have been proposed as a less toxic, less invasive therapeutic option to transhepatic arterial chemoembolization (TACE) for patients with surgically unresectable hepatocellular carcinoma (HCC). TACE has demonstrated the ability to prolong survival. However, long‐term survival remains uncertain. METHODS: In a 2‐cohort experience in the treatment of North American patients who had advanced, unresectable, biopsy‐proven HCC, 691 patients received repetitive, cisplatin‐based chemoembolization; and a separate cohort of 99 patients who had similar treatment criteria received a planned, single dose of ⁹⁰Y. Over the study period, an additional 142 patients were followed without treatment (total, 932 patients). RESULTS: Overall survival was slightly better in the ⁹⁰Y group compared with the TACE group (median survival, 11.5 months vs 8.5 months). However, the selection criteria indicated a small but significant bias toward milder disease in the ⁹⁰Y group. By using stratification into a 3‐tier model with patients dichotomized according to bilirubin levels 90Y and TACE appeared to be equivalent regional therapies for patients with unresectable, nonmetastatic HCC. Cancer 2010. © 2010 American Cancer Society.